GB201802339D0 - Immunogenic composition - Google Patents

Immunogenic composition

Info

Publication number
GB201802339D0
GB201802339D0 GBGB1802339.0A GB201802339A GB201802339D0 GB 201802339 D0 GB201802339 D0 GB 201802339D0 GB 201802339 A GB201802339 A GB 201802339A GB 201802339 D0 GB201802339 D0 GB 201802339D0
Authority
GB
United Kingdom
Prior art keywords
immunogenic composition
immunogenic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1802339.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB1802339.0A priority Critical patent/GB201802339D0/en
Publication of GB201802339D0 publication Critical patent/GB201802339D0/en
Priority to CN201980025676.7A priority patent/CN112153980A/zh
Priority to BR112020016373-2A priority patent/BR112020016373A2/pt
Priority to ARP190100345A priority patent/AR114627A1/es
Priority to EP19706423.1A priority patent/EP3752183A1/en
Priority to JP2020565545A priority patent/JP2021514387A/ja
Priority to IL276661A priority patent/IL276661B2/en
Priority to PCT/EP2019/053463 priority patent/WO2019158537A1/en
Priority to EA202091690A priority patent/EA202091690A1/ru
Priority to KR1020207025858A priority patent/KR20200121825A/ko
Priority to AU2019221496A priority patent/AU2019221496B2/en
Priority to MX2020008454A priority patent/MX2020008454A/es
Priority to SG11202007676RA priority patent/SG11202007676RA/en
Priority to US16/968,895 priority patent/US11426455B2/en
Priority to CA3090609A priority patent/CA3090609A1/en
Priority to US17/869,055 priority patent/US20230052495A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
GBGB1802339.0A 2018-02-13 2018-02-13 Immunogenic composition Ceased GB201802339D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1802339.0A GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition
CA3090609A CA3090609A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
IL276661A IL276661B2 (en) 2018-02-13 2019-02-12 Immunogenic preparation containing staphylococcal antigens
EA202091690A EA202091690A1 (ru) 2018-02-13 2019-02-12 Иммуногенная композиция, содержащая стафилококковые антигены
ARP190100345A AR114627A1 (es) 2018-02-13 2019-02-12 Composición inmunogénica
EP19706423.1A EP3752183A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
JP2020565545A JP2021514387A (ja) 2018-02-13 2019-02-12 ブドウ球菌抗原を含む免疫原性組成物
CN201980025676.7A CN112153980A (zh) 2018-02-13 2019-02-12 包含葡萄球菌抗原的免疫原性组合物
PCT/EP2019/053463 WO2019158537A1 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
BR112020016373-2A BR112020016373A2 (pt) 2018-02-13 2019-02-12 Composição imunogênica compreendendo antígenos de estafilococos
KR1020207025858A KR20200121825A (ko) 2018-02-13 2019-02-12 포도상구균 항원을 포함하는 면역원성 조성물
AU2019221496A AU2019221496B2 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
MX2020008454A MX2020008454A (es) 2018-02-13 2019-02-12 Composicion inmunogenica que comprende antigenos estafilococicos.
SG11202007676RA SG11202007676RA (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
US16/968,895 US11426455B2 (en) 2018-02-13 2019-02-12 Immunogenic composition comprising staphylococcal antigens
US17/869,055 US20230052495A1 (en) 2018-02-13 2022-07-20 Immunogenic composition comprising staphylococcal antigens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1802339.0A GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition

Publications (1)

Publication Number Publication Date
GB201802339D0 true GB201802339D0 (en) 2018-03-28

Family

ID=61731342

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1802339.0A Ceased GB201802339D0 (en) 2018-02-13 2018-02-13 Immunogenic composition

Country Status (15)

Country Link
US (2) US11426455B2 (https=)
EP (1) EP3752183A1 (https=)
JP (1) JP2021514387A (https=)
KR (1) KR20200121825A (https=)
CN (1) CN112153980A (https=)
AR (1) AR114627A1 (https=)
AU (1) AU2019221496B2 (https=)
BR (1) BR112020016373A2 (https=)
CA (1) CA3090609A1 (https=)
EA (1) EA202091690A1 (https=)
GB (1) GB201802339D0 (https=)
IL (1) IL276661B2 (https=)
MX (1) MX2020008454A (https=)
SG (1) SG11202007676RA (https=)
WO (1) WO2019158537A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511950A (zh) * 2019-07-29 2019-11-29 因之彩生物科技（武汉）有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
MY207887A (en) * 2020-05-01 2025-03-26 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen
JP7423133B2 (ja) 2020-09-21 2024-01-29 エルジー エナジー ソリューション リミテッド リチウム二次電池の活性化方法及びリチウム二次電池

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553776A (en) * 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
SG188102A1 (en) * 2008-01-31 2013-03-28 Trinity College Dublin Treatment of microbial infections
AU2015202532A1 (en) 2009-04-14 2015-06-04 Novartis Ag Compositions for immunising against Staphylococcus aureus
SA110310528B1 (ar) * 2009-06-22 2014-07-02 Wyeth Llc التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
US20140037650A1 (en) 2009-07-24 2014-02-06 University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
EP3281639B1 (en) * 2010-05-06 2020-11-11 GlaxoSmithKline Biologicals S.A. Capsular gram-positive bacteria bioconjugate vaccines
CA2803298C (en) * 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
EP2654784B1 (en) 2010-12-22 2016-12-07 Wyeth LLC Stable immunogenic compositions of staphylococcus aureus antigens
BR112014003315A2 (pt) * 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
US20150202277A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US10195262B2 (en) 2013-12-04 2019-02-05 Glaxosmithkline Biologicals S.A. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli
CN106103469B (zh) * 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511950A (zh) * 2019-07-29 2019-11-29 因之彩生物科技（武汉）有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用
CN110511950B (zh) * 2019-07-29 2022-03-08 因之彩生物科技（武汉）有限公司 Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用

Also Published As

Publication number Publication date
US11426455B2 (en) 2022-08-30
EA202091690A1 (ru) 2020-11-27
US20230052495A1 (en) 2023-02-16
WO2019158537A1 (en) 2019-08-22
CN112153980A (zh) 2020-12-29
KR20200121825A (ko) 2020-10-26
IL276661B2 (en) 2023-08-01
EP3752183A1 (en) 2020-12-23
US20210023192A1 (en) 2021-01-28
MX2020008454A (es) 2021-03-25
AR114627A1 (es) 2020-09-30
CA3090609A1 (en) 2019-08-22
AU2019221496B2 (en) 2022-12-08
AU2019221496A1 (en) 2020-08-27
BR112020016373A2 (pt) 2020-12-15
IL276661A (en) 2020-09-30
IL276661B1 (en) 2023-04-01
SG11202007676RA (en) 2020-09-29
JP2021514387A (ja) 2021-06-10

Similar Documents

Publication Publication Date Title
SG11202010821TA (en) Vaccine composition
GB201711635D0 (en) Immunogenic composition
GB201610599D0 (en) Immunogenic Composition
IL271603A (en) Immunogenic preparations
GB201810492D0 (en) Composition
GB201802339D0 (en) Immunogenic composition
GB201804434D0 (en) Composition
GB201811100D0 (en) Composition
SG11202009147UA (en) Vaccine compositions
EP3397277C0 (en) IMMUNOGENIC COMPOSITION
GB201820878D0 (en) Composition
GB201812145D0 (en) Composition
GB201711637D0 (en) Immunogenic composition
IL291559A (en) Immunogenic preparations
GB201818827D0 (en) Composition
GB201801596D0 (en) Composition
SG11202103389WA (en) Immunogenic compositions
GB201614485D0 (en) Immunogenic composition
EP3741388A4 (en) IMMUNOGENIC COMPOSITION
GB201901161D0 (en) Composition
GB201810024D0 (en) Composition
GB201703529D0 (en) Vaccine composition
GB201803692D0 (en) Immunogenic composition
GB201819861D0 (en) Composition
GB201815032D0 (en) Composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)